News
GRFS
7.55
+0.37%
0.03
Weekly Report: what happened at GRFS last week (0928-1002)?
Weekly Report · 2d ago
Grifols Refinanced Its Debt But the Plasma Strategy Hasn't Proven Itself Yet
Barchart · 4d ago
Weekly Report: what happened at GRFS last week (0921-0925)?
Weekly Report · 09/28 10:20
Grifols' Egypt Plasma Bet Either Validates the Turnaround or Exposes It
Barchart · 09/25 16:01
After Hours Most Active for Sep 23, 2026 : WBD, GRAB, NVDA, NIO, CMCSA, TTD, BMY, GRFS, PBR, RKT, RBLX, O
NASDAQ · 09/23 20:24
Weekly Report: what happened at GRFS last week (0914-0918)?
Weekly Report · 09/21 10:20
Grifols: Can Regional Plasma Sourcing Actually Fix What U.S. Reliance Broke?
Barchart · 09/18 16:01
Grifols: Better Plasma Economics Can Unlock A Discounted Equity
Seeking Alpha · 09/17 01:33
Weekly Report: what happened at GRFS last week (0907-0911)?
Weekly Report · 09/14 10:25
Grifols' Immunoglobulin Momentum: The One Franchise Holding the Turnaround Story Together
Barchart · 09/11 16:00
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
NASDAQ · 09/08 15:40
Weekly Report: what happened at GRFS last week (0831-0904)?
Weekly Report · 09/07 10:19
Weekly Report: what happened at GRFS last week (0824-0828)?
Weekly Report · 08/31 10:26
Grifols Reports Next Quarter After Refinancing Debt and Missing Estimates Twice in a Row
Barchart · 08/28 16:01
Weekly Report: what happened at GRFS last week (0817-0821)?
Weekly Report · 08/24 10:27
Can Grifols Prove the Immunoglobulin Momentum Justifies Ignoring the Plasma Collection Economics?
Barchart · 08/21 16:01
Oakmark International Small-Cap Strategy reshuffles portfolio with six new positions in Q2
Seeking Alpha · 08/18 13:52
Weekly Report: what happened at GRFS last week (0810-0814)?
Weekly Report · 08/17 10:28
Oakmark International Small Cap Strategy Q2 2026 Portfolio Update
Seeking Alpha · 08/15 05:25
Grifols Arrives at Earnings Having Already Declared Victory in July
Barchart · 08/14 16:01
More
Webull provides a variety of real-time GRFS stock news. You can receive the latest news about Grifols S A through multiple platforms. This information may help you make smarter investment decisions.
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.